ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Study of Oral Oteseconazole for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)

ClinicalTrials.gov ID: NCT03562156

Public ClinicalTrials.gov record NCT03562156. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 10:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oteseconazole (VT-1161) Oral Capsules in the Treatment of Subjects With Recurrent Vulvovaginal Candidiasis

Study identification

NCT ID
NCT03562156
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Mycovia Pharmaceuticals Inc.
Industry
Enrollment
438 participants

Conditions and interventions

Interventions

  • Oteseconazole (VT-1161) Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
12 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 15, 2018
Primary completion
Oct 18, 2020
Completion
Aug 5, 2021
Last update posted
Feb 16, 2026

2018 – 2021

United States locations

U.S. sites
25
U.S. states
16
U.S. cities
24
Facility City State ZIP Site status
31123 Birmingham Alabama 35233
31108 San Diego California 92111
31139 Lauderdale Lakes Florida 33319
31143 Sarasota Florida 34239
31106 Wellington Florida 33414
31111 Norcross Georgia 30095
31146 Covington Louisiana 70433
31105 Metairie Louisiana 70006
31107 Metarie Louisiana 70001
31147 Fall River Massachusetts 02720
31118 Las Vegas Nevada 89123
31103 Las Vegas Nevada 89128
31114 Lawrenceville New Jersey 08648
31142 Port Jefferson New York 11777
31127 West Seneca New York 14224
31132 Greensboro North Carolina 27408
31116 Morehead City North Carolina 28557
31144 Raleigh North Carolina 27607
31145 Winston-Salem North Carolina 27103
31125 Franklin Ohio 45005
31134 Philadelphia Pennsylvania 19102
31120 Bristol Tennessee 37620
31102 Houston Texas 77054
31117 Draper Utah 84020
31113 Richmond Virginia 23225

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03562156, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 16, 2026 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03562156 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →